Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
about
Systematic review of orogenital HIV-1 transmission probabilitiesInter-laboratory assessment of a prototype multiplex kit for determination of recent HIV-1 infectionUse of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infectionInfluenza and HIV: lessons from the 2009 H1N1 influenza pandemic.Performance characteristics of an antibody-based multiplex kit for determining recent HIV-1 infection.Clinical and Mucosal Immune Correlates of HIV-1 Semen Levels in Antiretroviral-Naive Men.A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.HIV dynamics in seminal plasma during primary HIV infectionPre-exposure prophylaxis and the promise of combination prevention approachesEvaluation of a multiplex assay for estimation of HIV-1 incidence.Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies.Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes.Chlamydia trachomatis Infection of Endocervical Epithelial Cells Enhances Early HIV Transmission Events.Assessment of provider-initiated HIV screening in Nigeria with sub-Saharan African comparisonLower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation.(C2) Saliva, breast milk, and mucosal fluids in HIV transmission.HIV incidence determination in the United States: a multiassay approach.Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection.The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with menA serial risk score approach to disease classification that accounts for accuracy and cost.Estimation of HIV incidence using multiple biomarkers.Cross-sectional HIV incidence estimation in HIV prevention research.Identifying people with acute HIV infection: demographic features, risk factors, and use of health care among individuals with AHI in North Carolina.HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithmSix-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.Higher viral load and genetic diversity of HIV-1 in seminal compartments than in blood of seven Chinese men who have sex with men and have early HIV-1 infection.Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.High HIV-1 RNA among Newly Diagnosed People in Botswana.Point of Care Diagnostics for HIV in Resource Limited Settings: An Overview
P2860
Q22242881-58EC749E-1461-4D67-A1BB-714055C50280Q28534491-2AFE747E-5B50-4F29-985D-947B19E0D7B3Q28743210-82310A38-A56E-4D93-99C8-3DFD15A3CA0CQ30404293-DC49CB50-89AA-4820-98F3-755D2A890B01Q33637675-287B1F35-F47A-4CB4-A4B5-D372C16CBA89Q33647158-6C50DFC9-A8B0-4E92-B6BD-AF00E98C2D47Q33812743-E621121A-3658-43E2-A2F8-017F1D212515Q34083267-F39AF6F6-B4DC-4464-B881-8916C42FB280Q34724603-D24C98E8-5C70-4A5B-8A3D-D7F4D1A9A103Q34745421-394DB050-C2F4-43EC-9D8D-BF4FF8BA1EE2Q34858876-58CD0537-D94E-4C5D-860D-35A0D31101A8Q35080053-3C54C879-D3B7-4DFD-9BE7-1A260306D1C2Q35690562-0A3B60DA-8ACC-4E75-9E09-675FCB3E4E85Q35885053-78034C0E-5650-48F4-BE35-F519014045FCQ36303243-C0E2DC54-57CD-46CC-B389-7D6679C98C30Q36414171-C0B403E9-EABB-4368-A8F9-9226FBE8D5F7Q36467686-3DE15228-2186-4BE2-A89A-414E2598459BQ36495553-686DE8F7-D41A-406C-B00C-4207BAD9802AQ36530346-E6FDA2A1-A89B-40B2-ADDE-AB31742CECE7Q36627938-B7289022-46D9-4144-8377-7BE08F3380F6Q36683821-E6AD51FA-96DA-4844-A356-3E8E8782CE3FQ36764936-28510125-7ADD-45FB-9BEE-FECA687B4889Q37080530-5593163B-6AD1-48A5-A1E8-9F71CE4F58D4Q37455868-97E21987-AE89-44D7-A4CA-C90B5BF08A1DQ37546766-5BBB9989-66A9-45B9-BDE7-FEA546DF9507Q38594555-58944054-2327-47BC-BDDB-04845AC63B23Q40202928-45E33DD7-E678-4AA3-A24E-15D8D8797431Q40751062-AB3D4323-FA23-4983-9BD2-DEF838271FF2Q45305937-7CB17A0C-CE6C-44D6-B9FD-32E1772A52C5Q57826025-10DB8A99-51C9-44E4-A5B4-C668BF1D9342
P2860
Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Early human immunodeficiency v ...... and genital tract virus load.
@ast
Early human immunodeficiency v ...... and genital tract virus load.
@en
type
label
Early human immunodeficiency v ...... and genital tract virus load.
@ast
Early human immunodeficiency v ...... and genital tract virus load.
@en
prefLabel
Early human immunodeficiency v ...... and genital tract virus load.
@ast
Early human immunodeficiency v ...... and genital tract virus load.
@en
P2093
P356
P1476
Early human immunodeficiency v ...... and genital tract virus load.
@en
P2093
Buchbinder SP
Douglas JM Jr
P356
10.1086/317658
P407
P577
2000-12-08T00:00:00Z